CGEM to Present Initial CLN-978 Clinical Data at EULAR 2026, Shows Favorable Safety Profile, Robust B Cell Depletion in RA and SLE Patients
Cullinan Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $16.44
-6.0% in 3d after detection
Post-detection moves
1h
—
1d
-4.7%
3d
-6.0%
7d
+3.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS